Isconova has its origin at the Swedish University of Agricultural Science (SLU) in Uppsala, where the ISCOM technology was invented by Professor Bror Morein and further developed by him and his and co-workers in the mid 1980s. More than 400 scientific publications from all around the world have since established a wide variety of attributes related to adjuvants based on ISCOM technology, especially their immunological properties.

Isconova was founded in 1999 as a spin-off from SLU to further develop its ISCOM technology and make it commercially available as a platform for vaccine development and improved off-the-shelf research adjuvants. Thanks to Isconova's unique combination of knowledge, experience and commercial insight, Isconova today occupies leading position in both areas.

1982 The ISCOM adjuvant technology was invented by Prof. B. Morein, SLU

1985 First patent granted

1990-1997 ISCOM technology developed in collaboration with CSL

1997 Human vaccines development program moved to CSL in Australia. Veterinary rights were spun-off and remained in Sweden under the name Advet AB

1999-2000 Isconova AB founded and acquires Advet AB

2000-2002 Development of base technology and a horse influenza vaccine

2002 License deal relating to generation II equine vaccine, to a major Veterinary Vaccine Development Company

2002-2004 Development of generation III ISCOM technology resulting in three new patent applications

2004 Long term contract manufacturing agreement awarded for Generation II ISCOMs (horse vaccines)

2005 Scale up of manufacturing

2005 License deal regarding the Isconova Low-tox adjuvant with a major Vaccine Development Company relating to human Flu and human RSV vaccines

2005 Excellent results from pre-IND safety studies

2006 FDA "no clinical hold" for initiation of clinical phase I studies in the US